



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/676,053	09/28/2000	James Oliver Dolly	A-05012DIV1(17044DIV1(AP) 2480		
33197 STOUT UXA	7590 08/22/200 RIIVAN & MIII I INS		EXAMINER		
STOUT, UXA, BUYAN & MULLINS LLP 4 VENTURE, SUITE 300			ZEMAN, ROBERT A		
IRVINE, CA 92618			ART UNIT	PAPER NUMBER	
			1645		
				I province and	
			MAIL DATE	DELIVERY MODE	
			08/22/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Commence	09/676,053	DOLLY ET AL.				
Office Action Summary	Examiner	Art Unit				
·	Robert A. Zeman	1645				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION  16(a). In no event, however, may a reply be tim  11 apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	I.  lety filed  the mailing date of this communication.  D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 04 Ju	ne 2007.					
	action is non-final.					
•						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) 31,32 and 34-45 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>31,32 and 34-45</u> is/are rejected.						
7) Claim(s) is/are objected to.	·					
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers	•					
··· ·	•					
9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correcti						
11) The oath or declaration is objected to by the Ex		•				
Priority under 35 U.S.C. § 119						
•	priority under 35 LLS C & 119(a)	or (f)				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1.☐ Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list		ed.				
Attachment(s)	A) Intention Comme	(RTO 413)				
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da					
3) Information Disclosure Statement(s) (PTO/SB/08)  5) Notice of Informal Patent Application						
Paper No(s)/Mail Date	6)	•				

#### DETAILED ACTION

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6-4-2007 has been entered.

The amendment filed on 6-4-2007 is acknowledged. Claims 31, 34, 36, 38 and 43-45 have been amended. Claims 31-32 and 34-35 are pending and currently under examination.

### Objections Withdrawn

#### Oath/Declaration

The objection to the oath or declaration as being defective by containing Non-initialed and/or non-dated alterations is withdrawn in light of the declaration filed on 6-4-2007.

#### Claim Rejections Withdrawn

The rejection of claims 31-32 and 34-45 under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Bizzini (U.S. Patent 4,594,336 -- IDS) is withdrawn. Said reference does not disclose an active neurotoxin which possesses mouse lethality of 3.3 x 10<sup>5</sup> LD<sub>50</sub>/mg or greater. It should be noted that this rejection may be reinstated depending on the resolution of the new matter rejection set forth below.

Art Unit: 1645

The rejection of claims 31-32, 35-41 and 44-45 are rejected under 35 U.S.C. 102(e) as being anticipated by Arnon (U.S. Patent 5,562,907 -- IDS) is withdrawn in light of Applicant's arguments.

# New Grounds of Rejection

## 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 31-32 and 34-45 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection.

Applicant has amended claims 31 and 38 to recite "wherein the active neurotoxin possesses mouse lethality of 3.3 x 10<sup>5</sup> LD<sub>50</sub>/mg or greater ..." This phrase does not appear in the specification, or original claims as filed. The portion of the specification cited by Applicant provides support for only a TeTx reconstituted with either native HC and LC or native HC and recombinant LC but for all the active neurotoxins encompassed by the instant claims. Therefore this limitation is new matter. Moreover, the newly added range has no upper limit and therefore cannot be supported by two data points.

Application/Control Number: 09/676,053

Art Unit: 1645

Conclusion

Page 4

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Zeman whose telephone number is (571) 272-0866.

The examiner can normally be reached on Monday- Thursday, 7am -5:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on (571) 272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>.

Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

PRIMARY EXAMINER

August 14, 2007